Insider trading

Period: 120 months Stock: TECH Share of holding: 50% or more × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

38 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

38 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

38 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

38 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
38 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
38 decisions over 120 months Remove this filter
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

38 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
8 May 2026
Herr Amy E. Director · indirect
Sold at will
$320.39K 6,636 at 48.28
97.1%
Sold half or more
17 Feb 2026
Herr Amy E. Director · indirect
Sold at will
$116.79K 1,976 at 59.11
90.8%
Sold half or more
19 Nov 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated 2×
$252.69K 500 at 505.38
100%
Sold half or more
12 Nov 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated 10×
$13.69M 27,159 at 504.00
95.4%
Sold half or more
22 Sep 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$434.87K 822 at 529.04
100%
Sold half or more
7 Sep 2021
STEER RANDOLPH C Director
Sold, plan not stated 3×
$4.08M 8,000 at 509.98
61.0%
Sold half or more
31 Aug 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated
$773.73K 1,538 at 503.07
53.9%
Sold half or more
12 Jul 2021
Hippel James Chief Financial Officer
Sold, plan not stated 13×
$4.57M 10,000 at 456.67
52.3%
Sold half or more
9 Jun 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$351.16K 811 at 433.00
100%
Sold half or more
7 Jun 2021
Hippel James Chief Financial Officer
Sold, plan not stated 6×
$4.19M 9,942 at 421.93
52.1%
Sold half or more
25 May 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$358.28K 845 at 424.00
51.0%
Sold half or more
12 Feb 2021
Hippel James Chief Financial Officer
Sold, plan not stated 2×
$4.00M 10,000 at 400.39
52.3%
Sold half or more
12 Feb 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 2×
$3.99M 10,000 at 398.64
62.0%
Sold half or more
5 Feb 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated 7×
$12.54M 32,933 at 380.68
96.2%
Sold half or more
11 Jan 2021
Hippel James Chief Financial Officer
Sold, plan not stated 6×
$3.34M 10,000 at 333.63
52.3%
Sold half or more
30 Nov 2020
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 3×
$3.28M 10,857 at 301.94
63.9%
Sold half or more
9 Nov 2020
Seth Alpna Director
Sold, plan not stated 2×
$1.54M 5,023 at 306.62
70.1%
Sold half or more
6 Nov 2020
STEER RANDOLPH C Director
Sold, plan not stated 6×
$3.02M 10,000 at 301.99
66.2%
Sold half or more
6 Nov 2020
HIGGINS JOHN L Director
Sold, plan not stated 3×
$1.50M 5,000 at 300.35
53.1%
Sold half or more
9 Jul 2020
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 8×
$2.50M 9,079 at 275.76
67.8%
Sold half or more
6 Jul 2020
Hippel James Chief Financial Officer
Sold, plan not stated 5×
$5.84M 21,502 at 271.61
69.8%
Sold half or more
29 May 2020
Eansor Norman David President-Protein Sciences
Sold, plan not stated 4×
$2.07M 7,909 at 262.00
100%
Sold half or more
28 May 2020
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 2×
$1.56M 5,995 at 260.14
58.2%
Sold half or more
28 May 2020
Eansor Norman David President-Protein Sciences
Sold, plan not stated
$897.13K 3,448 at 260.19
100%
Sold half or more
22 May 2020
Eansor Norman David President-Protein Sciences
Sold, plan not stated 2×
$3.38M 12,600 at 267.93
100%
Sold half or more
21 May 2020
Eansor Norman David President-Protein Sciences
Sold, plan not stated 2×
$2.95M 11,037 at 267.49
100%
Sold half or more
4 Mar 2020
Eansor Norman David President-Protein Sciences
Sold, plan not stated
$275.57K 1,387 at 198.68
100%
Sold half or more
12 Feb 2020
HIGGINS JOHN L Director
Sold, plan not stated
$1.03M 5,000 at 205.23
55.4%
Sold half or more
12 Dec 2019
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 4×
$1.72M 8,000 at 215.60
74.7%
Sold half or more
22 Nov 2019
Hippel James Chief Financial Officer
Sold, plan not stated 2×
$5.10M 23,651 at 215.59
71.8%
Sold half or more
21 Nov 2019
Hippel James Chief Financial Officer
Sold, plan not stated
$2.44M 11,349 at 215.36
54.9%
Sold half or more
12 Jun 2019
Eansor Norman David SVP - Novus Biologicals
Sold, plan not stated
$670.16K 3,117 at 215.00
100%
Sold half or more
4 Jun 2019
HIGGINS JOHN L Director
Sold, plan not stated
$1.02M 5,000 at 203.67
58.6%
Sold half or more
24 May 2019
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated
$1.08M 5,400 at 200.00
71.2%
Sold half or more
1 May 2019
Hippel James Chief Financial Officer
Sold, plan not stated
$7.11M 35,000 at 203.08
88.9%
Sold half or more
23 Aug 2018
HIGGINS JOHN L Director
Sold, plan not stated
$1.88M 10,000 at 187.92
76.9%
Sold half or more
6 Sep 2017
HOLBROOK KAREN A Director
Sold, plan not stated
$128.91K 1,059 at 121.73
53.7%
Sold half or more
25 May 2017
HOLBROOK KAREN A Director
Sold, plan not stated
$555.77K 5,000 at 111.15
71.7%
Sold half or more
Showing 1–38 of 38.